[
  {
    "ts": null,
    "headline": "Bristol Myers price target raised to $40 from $37 at Morgan Stanley",
    "summary": "Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37 and keeps an Underweight rating on the shares. 2026 revenue and EPS guidance came in above consensus, but was driven by a higher than expected Eliquis guide, the analyst tells investors in a research note.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximi",
    "url": "https://finnhub.io/api/news?id=6ec75702ca8315a61c81e17d746b9697e299d3e004f67d4b72ba3bdf4a5192d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770479139,
      "headline": "Bristol Myers price target raised to $40 from $37 at Morgan Stanley",
      "id": 138385773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Morgan Stanley analyst Terence Flynn raised the firm’s price target on Bristol Myers (BMY) to $40 from $37 and keeps an Underweight rating on the shares. 2026 revenue and EPS guidance came in above consensus, but was driven by a higher than expected Eliquis guide, the analyst tells investors in a research note.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximi",
      "url": "https://finnhub.io/api/news?id=6ec75702ca8315a61c81e17d746b9697e299d3e004f67d4b72ba3bdf4a5192d8"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug",
    "summary": "We recently published 12 Stocks Jim Cramer Talked About. Bristol Myers Squibb Company (NYSE:BMY) is one of the stocks that Jim Cramer talked about. Bristol Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. Its shares are up by 7.5% over the past year and by 15.4% year-to-date. Piper Sandler […]",
    "url": "https://finnhub.io/api/news?id=38954ffaa6d572d9ff4475b82404f7a56c82fda76f17355d9387a7f789589508",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770476929,
      "headline": "Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug",
      "id": 138385774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published 12 Stocks Jim Cramer Talked About. Bristol Myers Squibb Company (NYSE:BMY) is one of the stocks that Jim Cramer talked about. Bristol Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. Its shares are up by 7.5% over the past year and by 15.4% year-to-date. Piper Sandler […]",
      "url": "https://finnhub.io/api/news?id=38954ffaa6d572d9ff4475b82404f7a56c82fda76f17355d9387a7f789589508"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
    "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
    "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770453000,
      "headline": "Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More",
      "id": 138384854,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154390775/image_2154390775.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Big pharma Q4 2025 beats: Lilly leads obesity/diabetes, Novo faces 2026 pressure, LOE transitions in focus.",
      "url": "https://finnhub.io/api/news?id=f8944b09b7fd83e5420be2f4af05b504c53449ae617b3594f5665404d55c833d"
    }
  }
]